-+ 0.00%
-+ 0.00%
-+ 0.00%

*CervoMed Continued Progress Towards Initiating Planned Phase 3 Trial Evaluating Neflamapimod in Patients With Dementia With Lewy Bodies in 2H >CRVO

Dow Jones·05/18/2026 11:35:00

Please log in to view news